Skip to main content

Cardiomyopathies

2
Pipeline Programs
10
Companies
8
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Medtronic
MedtronicNJ - Phillipsburg
1 program
1
Clinical ReminderPhase 31 trial
Active Trials
NCT01217827Completed89Est. Dec 2013
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
ColchicinePhase 31 trial
Active Trials
NCT06158698Recruiting80Est. May 2028
Philips
PhilipsNetherlands - Amsterdam
1 program
CMR patchN/A1 trial
Active Trials
NCT06331507Terminated292Est. Jun 2023
GE HealthCare
1 program
Contrast Echocardiography Cost Effectiveness for Left Ventricular Thrombus AssessmentN/A1 trial
Active Trials
NCT02555527Completed500,000Est. Feb 2017
Zoll
ZollCA - San Jose
1 program
Heart Rate Monitor Enhanced Treatment OptimizationN/A1 trial
Active Trials
NCT04504188Recruiting300Est. Dec 2024
Berlin Heart
Berlin HeartTX - The Woodlands
1 program
Magnetocardiography scanN/A1 trial
Active Trials
NCT06689098Completed330Est. Dec 2024
Rocket Pharmaceuticals
1 program
PKP2-ACM Natural History StudyN/A1 trial
Active Trials
NCT06644742Recruiting36Est. Apr 2031
Boston Scientific
Boston ScientificCA - Valencia
1 program
Subcutaneous ICD with same day dischargeN/A1 trial
Active Trials
NCT03504839Completed53Est. Apr 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
UNION therapeuticsColchicine
MedtronicClinical Reminder
Rocket PharmaceuticalsPKP2-ACM Natural History Study
Berlin HeartMagnetocardiography scan
PhilipsCMR patch
ZollHeart Rate Monitor Enhanced Treatment Optimization
Boston ScientificSubcutaneous ICD with same day discharge
GE HealthCareContrast Echocardiography Cost Effectiveness for Left Ventricular Thrombus Assessment

Clinical Trials (8)

Total enrollment: 501,180 patients across 8 trials

NCT06158698UNION therapeuticsColchicine

CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine

Start: Nov 2023Est. completion: May 202880 patients
Phase 3Recruiting
NCT01217827MedtronicClinical Reminder

Implantable Cardioverter-Defibrillator Use in the VA System

Start: Apr 2010Est. completion: Dec 201389 patients
Phase 3Completed
NCT06644742Rocket PharmaceuticalsPKP2-ACM Natural History Study

PKP2-ACM Natural History Study

Start: Mar 2026Est. completion: Apr 203136 patients
N/ARecruiting
NCT06689098Berlin HeartMagnetocardiography scan

Magnetocardiography as a Diagnostic Screening Tool for Myocarditis and Other Types of Cardiomyopathy

Start: Dec 2022Est. completion: Dec 2024330 patients
N/ACompleted
NCT06331507PhilipsCMR patch

Refinement and Assessment of New MRI Technologies for Cardiovascular Exams Using the Phillips CMR Patch

Start: Sep 2021Est. completion: Jun 2023292 patients
N/ATerminated
NCT04504188ZollHeart Rate Monitor Enhanced Treatment Optimization

Optimizing Beta Blocker Dosage in Women While Using the Wearable Cardioverter Defibrillator

Start: Mar 2021Est. completion: Dec 2024300 patients
N/ARecruiting
NCT03504839Boston ScientificSubcutaneous ICD with same day discharge

Same Day Subcutaneous ICD And Send Home (DASH)

Start: Jan 2018Est. completion: Apr 201953 patients
N/ACompleted
NCT02555527GE HealthCareContrast Echocardiography Cost Effectiveness for Left Ventricular Thrombus Assessment

Contrast Echocardiography Cost Effectiveness for Left Ventricular Thrombus Assessment

Start: Sep 2015Est. completion: Feb 2017500,000 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
3 actively recruiting trials targeting 501,180 patients
10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.